News - Medicago, a leading company in the development and production of plant-based therapeutic proteins and vaccines, will contribute one-third of the financing for the new Class 3 (CL3) containment laboratory to be located at Université Laval's Infectious Disease Research Center. The announcement of Medicago's half-million dollar investment was made today at Quebec City Hall. The City and the research centre's foundation will provide the remaining funds required to launch laboratory operations.
News - TSO3, an innovator in sterilization technology for medical devices in healthcare settings, has added to its label claims for the STERIZONE® VP4 sterilizer in Canada that validates the ability to sterilize a specific duodenoscope.
News - Opsens Inc. is pleased to announce receipt of orders worth over $1.2 millionfor its products to measure Fractional Flow Reserve ("FFR") from the Japanese market. Opsens' FFR products are designed to optimize the diagnostic and guide treatment in patients with coronary heart disease. The orders placed by Opsens' Japanese distributor, a player in interventional cardiology at the head of a well-organized distribution network, more than double Opsens' FFR revenues from fiscal year 2015.
News - B-TEMIA Inc., the market leader in human augmentation, today announced that it has initiated a multi-centre pivotal clinical trial, aimed at demonstrating the superior clinical benefits and safety for home use of its powered assistive Demoskeleton™ technology, called Keeogo™, for patients suffering from reduced mobility due to their medical conditions. Led by Principal Investigator, Dr. Chris A. McGibbon, PhD, from the University of New Brunswick's, Faculty of Kinesiology and Institute of Biomedical Engineering, the study is expected to generate the required data to support the submission of a 510(k) pre-market notification to the U.S. Food and Drug Administration in 2016, a prerequisite to start commercialization in the United States.
News - Opsens Inc. is pleased to announce it has been granted CE marking for the OptoWire II, the improved version of its pressure guidewire (OptoWire I) developed to measure Fractional Flow Reserve ("FFR") in patients with coronary artery disease. CE marking allows Opsens to sell OptoWire II in Europe, the world's second largest market.
News - Opsens Inc. is pleased to announce that the OptoWire and OptoMonitor, its products to measure Fractional Flow Reserve ("FFR"), were used for the first time in the United States by Dr. Morton J. Kern and Dr. Arnold Seto at the University of California, Irvine and VA Long Beach, California. Opsens' FFR products are designed for the diagnostic of the functional severity of coronary stenoses and to guide their treatment.
News - Canadian company B-Temia, Inc. and French company Sagem (Safran) announced the signature of a technological and business development agreement concerning a new-generation of exoskeletons for industrial and military applications. Exoskeletons are bio-mechanical and electronic structures worn on the body to assist and enhance people's movements, or to restore mobility.
News - Medicago, a leading Canadian company in the development and production of plant-based therapeutics and vaccines, has been awarded a contract by the Public Health Agency of Canada (PHAC) to develop two antibodies to fight the Sudan strain of the Ebola virus. Medicago will produce these antibodies at its facility in Quebec City.
News - Nordic Life Science Pipeline Inc. («Nordic») is proud to announce the launch of SQIN™ Body and SQIN ™ Hand & Foot, its first two cosmeceutical products to reach market. SQIN™ constitutes a unique line of skin products specifically designed and adapted for persistent and severe chronic dry skin problems found often in people suffering of paralysis or mobility impairment attributed to age, amputation, neurological and musculoskeletal problems or metabolic disorders.
News - Nordic Life Science Pipeline Inc. is proud to announce completion of the first clinical trials of Spinalon™, an oral pill composed of three active molecular entities capable together of triggering within minutes short bouts of locomotor-like activity in the legs of spinal cord-injured patients who had been chronically paralyzed for years.